Major Neurocognitive Disorder: Symptoms, Causes, Diagnosis, and Treatment

Major neurocognitive disorder (NCD) is the clinical term used in the DSM-5-TR for what has historically been called dementia. It describes a significant acquired decline in one or more cognitive domains — such as memory, attention, language, executive function, perceptual-motor ability, or social cognition — that is severe enough to interfere with a person's ability to function independently in everyday life.

The word "acquired" is critical here. Major neurocognitive disorder is not an intellectual disability present from birth or early development. It represents a decline from a previous level of functioning, meaning the person once had cognitive abilities that have measurably deteriorated over time.

Major NCD is extremely common, particularly among older adults. According to the World Health Organization, approximately 55 million people worldwide live with dementia, and nearly 10 million new cases are diagnosed each year. The Alzheimer's Association estimates that in the United States alone, roughly 6.7 million adults aged 65 and older are living with Alzheimer's disease — the most common subtype. Prevalence increases sharply with age: while it affects roughly 5% of those over 65, rates climb to approximately 30–50% in individuals over 85.

Despite its prevalence, major neurocognitive disorder is not an inevitable part of normal aging. While mild forgetfulness can occur with age, the cognitive decline seen in major NCD is qualitatively and quantitatively different — it is more severe, progressive, and functionally disabling.

The DSM-5-TR requires evidence of significant cognitive decline from a previous level of performance in one or more of six cognitive domains. The decline must be substantial enough to interfere with independence in everyday activities. The six domains include:

• Complex attention: Difficulty sustaining attention, being easily distracted, needing extra time or strategies to accomplish tasks that were once routine.
• Executive function: Problems with planning, decision-making, working memory, mental flexibility, and responding to feedback. A person may struggle to manage finances, organize a meal, or follow multi-step instructions.
• Learning and memory: Repeating oneself in conversation, difficulty recalling recent events, needing frequent reminders, or losing track of lists and appointments. In more advanced stages, even well-learned information — such as personal history — may be lost.
• Language: Difficulty finding words, using incorrect words, or struggling to follow or participate in conversations. Reading and writing may also be affected.
• Perceptual-motor function: Getting lost in familiar environments, difficulty using tools or dressing, or problems with spatial awareness that cannot be explained by vision impairment.
• Social cognition: Changes in behavior, personality, or the ability to recognize emotions in others. A person may become socially inappropriate, apathetic, or show poor judgment in interpersonal situations.

Beyond cognitive symptoms, common behavioral and psychological warning signs include:

• Wandering or becoming lost in familiar places — a significant safety risk
• Increased agitation, irritability, or suspiciousness
• Withdrawal from social activities or hobbies
• Difficulty managing medications, finances, or household tasks
• Changes in sleep patterns or appetite
• Personality changes that are noticeable to family and friends

A hallmark feature distinguishing major NCD from the milder form (mild neurocognitive disorder) is functional dependence. The individual requires assistance with complex instrumental activities of daily living, such as paying bills, managing medications, or shopping — and in later stages, even basic activities like bathing, dressing, and eating.

Major neurocognitive disorder is not a single disease but a syndrome with multiple possible etiologies. The DSM-5-TR specifies the underlying cause as a subtype. The most common causes include:

• Alzheimer's disease: The most prevalent cause, accounting for 60–80% of cases. It involves progressive accumulation of amyloid plaques and neurofibrillary tau tangles in the brain, leading to neuronal death. Onset is typically insidious, with memory impairment as the earliest and most prominent feature.
• Vascular disease: The second most common cause, resulting from cerebrovascular events such as strokes or chronic small-vessel disease. Cognitive decline may follow a stepwise pattern, and symptoms often depend on which brain regions are affected.
• Lewy body disease: Characterized by fluctuating cognition, visual hallucinations, and parkinsonism (motor symptoms resembling Parkinson's disease). Lewy bodies — abnormal protein deposits — accumulate in nerve cells.
• Frontotemporal lobar degeneration: Tends to affect younger individuals (ages 45–65) and primarily impacts personality, behavior, and language rather than memory in early stages.
• Traumatic brain injury: Repeated or severe head injuries can lead to neurocognitive decline, as seen in chronic traumatic encephalopathy (CTE).
• Parkinson's disease: Cognitive decline develops in a substantial proportion of people with Parkinson's, typically later in the disease course.
• HIV infection, prion disease, Huntington's disease, and substance/medication use: Less common but recognized etiologies in the DSM-5-TR classification.

Key risk factors include:

• Age: The single strongest risk factor. Risk roughly doubles every five years after age 65.
• Genetics: The APOE ε4 allele significantly increases risk for Alzheimer's disease. Rare autosomal dominant mutations (APP, PSEN1, PSEN2) cause early-onset familial forms.
• Cardiovascular risk factors: Hypertension, diabetes, obesity, high cholesterol, and smoking all increase risk, particularly for vascular and Alzheimer's-related neurocognitive disorders.
• Lower educational attainment and reduced cognitive engagement: Research supports the concept of "cognitive reserve" — individuals with more education, complex occupational histories, and ongoing mental engagement may show greater resilience to brain pathology.
• Depression: Both a risk factor for and a frequent co-occurring condition with major NCD.
• Social isolation and physical inactivity: Consistently identified as modifiable risk factors in large epidemiological studies.
• Hearing loss: Emerging evidence identifies midlife hearing loss as one of the most significant modifiable risk factors for dementia.

Diagnosis of major neurocognitive disorder involves a comprehensive, multi-step evaluation that integrates clinical history, cognitive testing, laboratory work, and neuroimaging. There is no single test that confirms the diagnosis.

Step 1: Clinical History and Informant Interview

The clinician gathers a detailed history from the individual and, critically, from a reliable informant — typically a family member or close friend. This helps establish the timeline, pattern, and severity of cognitive decline and its impact on daily functioning. The informant's perspective is essential because individuals with major NCD often have limited awareness of their own deficits (a phenomenon called anosognosia).

Step 2: Cognitive Screening

Brief screening instruments are commonly used in primary care and specialty settings:

• Montreal Cognitive Assessment (MoCA): A widely used 30-point screening tool that assesses multiple cognitive domains, including visuospatial ability, executive function, attention, language, abstraction, delayed recall, and orientation. A score below 26 generally warrants further evaluation.
• Mini-Cog: A rapid three-minute screen involving a three-word recall and a clock-drawing task. It is particularly useful in busy clinical settings for its brevity and reliability.

Step 3: Formal Neurocognitive (Neuropsychological) Evaluation

When screening suggests significant cognitive decline, a comprehensive neuropsychological assessment is recommended. This involves standardized tests that measure performance across all six cognitive domains, compared to age- and education-matched norms. This evaluation helps characterize the specific pattern and severity of impairment and can aid in identifying the likely underlying etiology.

Step 4: Medical Workup

A thorough medical evaluation is essential to identify treatable causes and rule out conditions that mimic major NCD:

• Blood tests: thyroid function, vitamin B12, complete metabolic panel, complete blood count, syphilis screening (RPR), and sometimes HIV testing
• Neuroimaging: Structural MRI or CT of the brain to identify strokes, tumors, hydrocephalus, or patterns of atrophy suggestive of specific etiologies
• In some cases, advanced imaging (FDG-PET, amyloid PET) or cerebrospinal fluid (CSF) biomarkers may be used to support a diagnosis of Alzheimer's disease

Step 5: Ruling Out Other Conditions

Two conditions that must be carefully distinguished from major NCD are:

• Delirium: An acute, fluctuating disturbance in attention and awareness typically caused by a medical condition, medication, or substance. Delirium develops rapidly (hours to days) and is often reversible. Major NCD should not be diagnosed during an active delirium episode, though the two conditions can co-occur.
• Depression-related cognitive symptoms ("pseudodementia"): Major depressive disorder can produce significant cognitive impairment, particularly in older adults. Depressive cognitive changes tend to have a more acute onset, are often accompanied by prominent mood symptoms, and may improve with antidepressant treatment.

Treatment of major neurocognitive disorder is complex, targeting cognitive symptoms, behavioral and psychological symptoms, safety, and caregiver support. While most etiologies do not have curative treatments, meaningful interventions can improve quality of life and slow functional decline.

Pharmacological Treatments

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine): These are first-line medications for Alzheimer's disease-related NCD. They work by increasing acetylcholine levels in the brain, modestly improving or stabilizing cognition and function for a period of months to years. They are most effective in mild to moderate stages.
• Memantine: An NMDA receptor antagonist used in moderate to severe Alzheimer's-related NCD, sometimes in combination with a cholinesterase inhibitor. It can help with cognition, behavior, and functional abilities.
• Anti-amyloid monoclonal antibodies (e.g., lecanemab, donanemab): Newer disease-modifying therapies that target amyloid-beta plaques. Clinical trials have demonstrated modest slowing of cognitive decline in early-stage Alzheimer's disease, though they carry risks including amyloid-related imaging abnormalities (ARIA). These treatments represent an emerging and evolving area of research.
• Management of behavioral and psychological symptoms: When non-pharmacological approaches are insufficient, judicious use of medications may be considered for agitation, psychosis, depression, or sleep disturbance. Selective serotonin reuptake inhibitors (SSRIs) are often preferred for depression and some behavioral symptoms. Antipsychotics are used cautiously and typically as a last resort due to increased mortality risk in older adults with dementia (FDA black box warning).

Non-Pharmacological Interventions

• Cognitive stimulation therapy (CST): Structured group activities designed to actively engage cognitive and social functioning. Research supports its effectiveness in improving cognition and quality of life in mild to moderate dementia.
• Physical exercise: Regular aerobic exercise has been shown to support cognitive function, reduce behavioral symptoms, and improve mood and sleep in individuals with major NCD.
• Occupational therapy: Focused on maintaining independence in daily activities through environmental modifications, assistive devices, and task simplification strategies.
• Music therapy and reminiscence therapy: These approaches leverage preserved long-term memories and emotional responsiveness to improve engagement, reduce agitation, and enhance well-being.
• Structured routines and environmental modifications: Consistent daily schedules, clear signage, adequate lighting, and removal of safety hazards can reduce confusion and agitation.
• Caregiver education and support: Caregivers of individuals with major NCD are at high risk for burnout, depression, and physical health problems. Evidence-based caregiver interventions — including psychoeducation, respite care, support groups, and skills training — are a critical component of comprehensive management.

The prognosis of major neurocognitive disorder depends heavily on the underlying etiology. In most cases, the condition is progressive and irreversible, though the rate and pattern of decline vary significantly.

• Alzheimer's disease: Typically follows a gradual, progressive course over 8–12 years from diagnosis, though some individuals live 20 years or more. The disease progresses through recognizable stages — from mild memory impairment and functional difficulties, through moderate stages with increasing dependence, to severe stages where the individual requires total care and may lose the ability to walk, swallow, or communicate.
• Vascular neurocognitive disorder: May follow a stepwise or fluctuating course, with periods of stability punctuated by acute declines — often corresponding to new cerebrovascular events. Aggressive management of cardiovascular risk factors can slow progression.
• Lewy body disease: Often progresses more rapidly than Alzheimer's, with prominent fluctuations in cognition, hallucinations, and motor symptoms complicating care.
• Frontotemporal degeneration: Typically has a faster course, with average survival of 6–8 years from symptom onset, though this varies widely.

It is essential to recognize that while cognitive decline is the defining feature, quality of life can be meaningfully supported throughout the disease course. Early diagnosis allows for advance care planning, legal and financial preparation, access to support services, and the implementation of interventions that can improve day-to-day functioning and well-being.

A small proportion of neurocognitive disorders are partially or fully reversible when caused by treatable conditions such as normal pressure hydrocephalus, thyroid dysfunction, vitamin B12 deficiency, medication side effects, or infections. This is why a thorough medical workup is essential — identifying and treating reversible causes can lead to significant cognitive improvement.

Major neurocognitive disorder exists on a spectrum and overlaps with several related conditions:

• Mild neurocognitive disorder: The less severe form, in which cognitive decline is noticeable and measurable but does not significantly interfere with independence. Many individuals with mild NCD eventually progress to major NCD, though not all do. Mild NCD corresponds roughly to what is often called "mild cognitive impairment" (MCI) in clinical practice.
• Delirium: An acute confusional state that can mimic or co-occur with major NCD. Distinguishing between the two is critical because delirium is often treatable and reversible.
• Major depressive disorder: Depression frequently co-occurs with major NCD and can also cause cognitive symptoms that resemble dementia. In older adults, depression and neurocognitive disorder may be difficult to disentangle and sometimes coexist.
• Parkinson's disease: Up to 80% of individuals with Parkinson's disease eventually develop cognitive impairment or dementia over the course of the illness.
• Substance-induced neurocognitive disorder: Chronic heavy alcohol use and certain other substances can cause lasting cognitive impairment that meets criteria for major NCD.
• Traumatic brain injury-related neurocognitive disorder: Cognitive decline following single severe or repeated mild traumatic brain injuries, as seen in athletes and military personnel.

Cognitive changes should be evaluated by a healthcare professional when they go beyond ordinary forgetfulness. Seek evaluation promptly if you or a loved one experiences:

• Memory problems that disrupt daily life — forgetting important appointments, repeating questions, or getting lost in familiar places
• Difficulty with tasks that were previously routine, such as managing finances, following recipes, or operating familiar devices
• Noticeable changes in judgment, planning ability, or problem-solving
• Word-finding difficulties or trouble following conversations
• Personality or behavioral changes — increased apathy, social withdrawal, agitation, or suspiciousness
• Confusion about time, place, or the identity of familiar people

Seek urgent evaluation in the following situations:

• Sudden cognitive decline: Rapid changes occurring over hours or days suggest delirium or stroke and require immediate medical attention.
• Wandering and safety risks: If a person with cognitive impairment is wandering, leaving the stove on, getting lost, or engaging in behaviors that put themselves or others at risk, immediate intervention and safety planning are necessary.
• Caregiver distress: If you are caring for someone with major neurocognitive disorder and feel overwhelmed, exhausted, depressed, or unable to provide safe care, seeking help is not a sign of failure — it is an essential part of sustainable caregiving. Caregiver burnout is a serious and well-documented phenomenon that requires professional support.

A primary care physician, geriatrician, neurologist, or geriatric psychiatrist can initiate evaluation. Neuropsychologists provide detailed cognitive assessments. Many communities also have memory clinics or dementia assessment programs that offer comprehensive, multidisciplinary evaluations.

Early diagnosis matters. Even in the absence of a cure, early identification allows for treatment that can slow decline, planning for future care needs, access to clinical trials, legal and financial preparation, and support services that meaningfully improve quality of life for both the individual and their family.